Literature DB >> 29796873

Atorvastatin and Caffeine in Combination Regulates Apoptosis, Migration, Invasion and Tumorspheres of Prostate Cancer Cells.

Zhenshi Wang1, Lanyue Zhang1, Zheng Wan2, Yan He1, Huarong Huang1, Hongping Xiang3, Xiaofeng Wu1, Kun Zhang1,4, Yang Liu5, Susan Goodin6, Zhiyun Du7, Xi Zheng8,9.   

Abstract

Atorvastatin is the most prescribed cholesterol-lowering statin, while caffeine enhances chemo-sensitivity and induces apoptosis of tumor cells through its DNA repair-inhibiting effect. The present study investigated the effects and mechanisms of atorvastatin and caffeine in combination on human prostate cancer cells cultured in vitro. Cell growth were determined by the trypan blue exclusion assay. The cell apoptosis and colony formation were determined by morphological assessment. The ability of cell migration and invasion were performed using a scratch wound-healing and Transwell assay. Tumorspheres were formed in suspension under the condition of non-adherence and serum-free medium. Finally, the western blot assay was used to determine the levels of proteins. The combination synergistically suppressed proliferation and induced apoptotic death. Meanwhile, the migration, invasion, and the formation of tumorspheres were significantly inhibited by the combination. We found that atorvastatin and caffeine in combination downregulated phospho-Akt, phospho-Erk1/2, anti-apoptotic Bcl-2 and Survivin protein levels. Results of the present study indicate treatment with the combination of caffeine and atorvastatin may be an effective strategy for inhibiting the growth of prostate cancer and should be evaluated clinically.

Entities:  

Keywords:  Apoptosis; Atorvastatin; Caffeine; Combination treatment; Prostate cancer

Mesh:

Substances:

Year:  2018        PMID: 29796873     DOI: 10.1007/s12253-018-0415-7

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  34 in total

Review 1.  Regulation of the mevalonate pathway.

Authors:  J L Goldstein; M S Brown
Journal:  Nature       Date:  1990-02-01       Impact factor: 49.962

Review 2.  Current and future treatment of hyperlipidemia: the role of statins.

Authors:  M Farnier; J Davignon
Journal:  Am J Cardiol       Date:  1998-08-27       Impact factor: 2.778

Review 3.  Ras and Rho regulation of the cell cycle and oncogenesis.

Authors:  K Pruitt; C J Der
Journal:  Cancer Lett       Date:  2001-09-28       Impact factor: 8.679

4.  Genistein inhibits the stemness properties of prostate cancer cells through targeting Hedgehog-Gli1 pathway.

Authors:  Linlin Zhang; Lei Li; Min Jiao; Dapeng Wu; Kaijie Wu; Xiang Li; Guodong Zhu; Lin Yang; Xinyang Wang; Jer-Tsong Hsieh; Dalin He
Journal:  Cancer Lett       Date:  2012-04-03       Impact factor: 8.679

5.  Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine.

Authors:  J N Sarkaria; E C Busby; R S Tibbetts; P Roos; Y Taya; L M Karnitz; R T Abraham
Journal:  Cancer Res       Date:  1999-09-01       Impact factor: 12.701

6.  Inhibition of progression of androgen-dependent prostate LNCaP tumors to androgen independence in SCID mice by oral caffeine and voluntary exercise.

Authors:  Xi Zheng; Xiao-Xing Cui; Mou-Tuan Huang; Yue Liu; George C Wagner; Yong Lin; Weichung Joe Shih; Mao-Jung Lee; Chung S Yang; Allan H Conney
Journal:  Nutr Cancer       Date:  2012       Impact factor: 2.900

7.  Caffeine inhibits the proliferation of liver cancer cells and activates the MEK/ERK/EGFR signalling pathway.

Authors:  Jun-ichi Okano; Takakazu Nagahara; Kazuya Matsumoto; Yoshikazu Murawaki
Journal:  Basic Clin Pharmacol Toxicol       Date:  2008-03-16       Impact factor: 4.080

8.  Simvastatin blocks TGF-β1-induced epithelial-mesenchymal transition in human prostate cancer cells.

Authors:  Feng Xie; Jie Liu; Chengwen Li; Yaorui Zhao
Journal:  Oncol Lett       Date:  2016-04-01       Impact factor: 2.967

9.  Statin use and risk of prostate cancer in the California Men's Health Study cohort.

Authors:  E Dawn Flick; Laurel A Habel; K Arnold Chan; Stephen K Van Den Eeden; Virginia P Quinn; Reina Haque; Endel J Orav; John D Seeger; Marianne C Sadler; Charles P Quesenberry; Barbara Sternfeld; Steven J Jacobsen; Rachel A Whitmer; Bette J Caan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-10-30       Impact factor: 4.254

10.  The Effects and Mechanism of YK-4-279 in Combination with Docetaxel on Prostate Cancer.

Authors:  Lin Yu; Xiaofeng Wu; Min Chen; Huarong Huang; Yan He; Huaqian Wang; Dongli Li; Zhiyun Du; Kun Zhang; Susan Goodin; Xi Zheng
Journal:  Int J Med Sci       Date:  2017-04-07       Impact factor: 3.738

View more
  6 in total

Review 1.  Current perspectives on statins as potential anti-cancer therapeutics: clinical outcomes and underlying molecular mechanisms.

Authors:  Ali Fatehi Hassanabad
Journal:  Transl Lung Cancer Res       Date:  2019-10

2.  Integrated microbiome, metabolome, and proteome analysis identifies a novel interplay among commensal bacteria, metabolites and candidate targets in non-small cell lung cancer.

Authors:  Xiang Qian; Hong-Yan Zhang; Qing-Lin Li; Guan-Jun Ma; Zhuo Chen; Xu-Ming Ji; Chang-Yu Li; Ai-Qin Zhang
Journal:  Clin Transl Med       Date:  2022-06

3.  Combined anticancer effects of simvastatin and arsenic trioxide on prostate cancer cell lines via downregulation of the VEGF and OPN isoforms genes.

Authors:  Akram Mirzaei; Sina Rashedi; Mohammad Reza Akbari; Fatemeh Khatami; Seyed Mohammad Kazem Aghamir
Journal:  J Cell Mol Med       Date:  2022-04-02       Impact factor: 5.295

Review 4.  Statins: a repurposed drug to fight cancer.

Authors:  Wen Jiang; Jin-Wei Hu; Xu-Ran He; Wei-Lin Jin; Xin-Yang He
Journal:  J Exp Clin Cancer Res       Date:  2021-07-24

5.  Caffeine Induces G0/G1 Cell Cycle Arrest and Inhibits Migration through Integrin αv, β3, and FAK/Akt/c-Myc Signaling Pathway.

Authors:  Pichitchai Meisaprow; Nithikoon Aksorn; Chanida Vinayanuwattikun; Pithi Chanvorachote; Monruedee Sukprasansap
Journal:  Molecules       Date:  2021-12-17       Impact factor: 4.411

6.  Atorvastatin attenuates intermittent hypoxia-induced myocardial oxidative stress in a mouse obstructive sleep apnea model.

Authors:  Xiao-Bin Zhang; Hui-Juan Cheng; Ya-Ting Yuan; Yan Chen; Yi-Yuan Chen; Kam Yu Chiu; Hui-Qing Zeng
Journal:  Aging (Albany NY)       Date:  2021-07-21       Impact factor: 5.682

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.